Arkolith/Insider Trading/LEXX/Form 4

Christopher Richard

Chief Executive OfficerLexaria Bioscience Corp. (LEXX) · full profile →Form 4 · filed Dec 3, 2024
Net Buying
Open-Market Buys
$118K
Open-Market Sells
$0
Net Open-Market Flow
$118K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 3, 2024Buy(P)27K$2.47$67K50K
Dec 2, 2024Buy(P)23K$2.24$51K23K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001348362-24-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML